Ultragenyx Targets 2027 Profitability and $1 Billion Revenue
Ultragenyx Pharmaceutical said it expects to become profitable in 2027, with revenue approaching $1 billion that year, executives told investors at the UBS Global Biopharma Conference. Chief Executive Emil Kakkis described the expected profitability as meaningful and tied the outlook to lower spending, growing sales of the company's existing rare-disease therapies and the launch of two gene therapies.
The forecast follows a period of setbacks for the company, and it comes after deep cost reductions. Ultragenyx reported revenue of 673.0 million USD in fiscal 2025 alongside a net loss of 575.0 million USD for the same year.
The company's next scheduled earnings report is set for Feb 11, 2027, when investors are expected to see early progress against the 2027 goals.